Abstract: Disclosed are methods for treating conditions characterized by anemia or red blood cells dysfunction by administering an agent that increases the level of endogenous LCAT or LCAT activity. Additionally disclosed are methods of treating conditions wherein red blood cells have reduced function in relation to deformability, oxygenation, increased adhesion and aggregability, reduced nitric oxide function, or decreased life-span, increased free cholesterol, or abnormal concentration of free cholesterol in red blood cells and methods of normalizing the free cholesterol content of red blood cells.
Type:
Application
Filed:
July 19, 2013
Publication date:
January 23, 2014
Applicant:
AlphaCore Pharma, LLC
Inventors:
Bruce J. AUERBACH, Brian KRAUSE, Reynold HOMAN
Abstract: Disclosed are compositions and methods for treating conditions characterized by low HDL-CE which can lead to decreased delivery of cholesteryl ester to steroidogenic tissues, reducing the organ's ability to produce steroids especially during periods of demand, stress and or systemic inflammatory response syndrome.
Type:
Application
Filed:
May 6, 2011
Publication date:
February 21, 2013
Applicant:
ALPHACORE PHARMA, LLC
Inventors:
Bruce J. Auerbach, Reynold Homan, Brian R. Krause